Converting HR+ Breast Cancer Into an Individualized Vaccine
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: RADIATION: Focal Radiation therapy|DRUG: Pembrolizumab (200mg IV for 30 minutes|BIOLOGICAL: CDX-301
Sponsor: Weill Medical College of Cornell University
Collaborators: United States Department of Defense|Merck Sharp & Dohme LLC|Celldex Therapeutics